단일기관에서 경험한 미만성 거대 B 세포 림프종의 Rituximab 사용후 향상된 치료효과 = Improved Therapeutic Outcomes of Diiffuse Large B cell Lymphoma after Introduction of Rituximab in a Single Institution

다국어 초록 (Multilingual Abstract)

Background : Diffuse large B cell lymphoma(DLBCL) is the most common type of non Hodgkin lymphoma and its prevalence is recently increasing . Rituximab combined chemotherapy is proved to be a standard treatment of DLBCL, and patients treated with Rituximab combined chemotherapy are known to have more longer survival than patients with chemotherapy alone. This study was performed retrospectively to compare the survival rates of Rituximab combined chemotherapy with those of chemotherapy only at the single institution.
Patients and Methods : From Sep 2001 to Feb 2008, DLBCL patients were newly diagnosed at the department of hemato-oncology at the Kosin University Gospel Hospital and they were included in this study. The median age of all the 73 patients was 53 years old(range 23-81 years). All the patients were devided into the Rituximab-combined CHOP(cyclophosphamide, vincristine, adramycin, prednisone) group(n=35) and CHOP only(n=38). The chemotherapeutic drugs and cycles were the same in patients of both groups. We analyzed the results of complete response(CR) rate, relapse free survival(RFS), and overall survival(OS) between the two groups. We, also, compared the results of survival rate according to intenational prognostic index (IPI).
Results : CR rate was higer in R-CHOP group than in CHOP group(97.1% vs 76.3%, p=0.01). Two years RFS rate was higher in R-CHOP group than in CHOP group(95.8% vs 65.5%, p=0.005). And 2 year OS rate was higher in R-CHOP group than in CHOP group(85.8% vs 65.8%, p=0.071).
Conclusion : In patients with DLBCL, CR rate, and 2 year RFS and OS rates were significantly higher in R-CHOP group than in CHOP group. Long term follow-up are needed to confirm these results.

목차 (Table of Contents)

• 서론
• 연구대상 및 방법
• 1. 연구대상
• 2. 연구방법
• 3. 통계적 분석
• 결 과
• 대상 환자의 임상적 특징
• 치료 효과
• 고찰
• 결론
• 참고문헌